Avandia is a diabetes drug. The FDA has just announced a more strict labelling for this drug though it appears Avandia will stay on the market.
The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia. However, other published and unpublished data from long-term clinical trials of Avandia, including an interim analysis of data from the RECORD trial (a large, ongoing, randomized open label trial) and unpublished reanalyses of data from DREAM (a previously conducted placebo-controlled, randomized trial) provide contradictory evidence about the risks in patients treated with Avandia.
Patients who are taking Avandia, especially those who are known to have underlying heart disease or who are at high risk of heart attack should talk to their doctor about this new information as they evaluate the available treatment options for their type 2 diabetes.
Here is news about Avandia
Avandia Company Website
Avandia from Drugs .com
FDA Safety Alert - Avandia
Showing posts with label fda. Show all posts
Showing posts with label fda. Show all posts
Thursday, November 15, 2007
Avandia. A Prescription Drug for Diabetes
at
Thursday, November 15, 2007
0
comments
Labels: avandia, fda, glaxo smith kline
Subscribe to:
Posts (Atom)